A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,334

Participants

Timeline

Start Date

November 9, 2012

Primary Completion Date

April 20, 2017

Study Completion Date

January 20, 2026

Conditions
Hodgkin Lymphoma
Interventions
DRUG

brentuximab vedotin

Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.

DRUG

doxorubicin

Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

DRUG

bleomycin

Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

DRUG

vinblastine

Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

DRUG

dacarbazine

Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Trial Locations (215)

Unknown

Birmingham

Gilbert

Tucson

Burbank

Duarte

Fresno

Fullerton

La Jolla

Long Beach

Los Angeles

Sacramento

San Luis Obispo

Santa Barbara

Santa Monica

Stanford

Colorado Springs

Denver

Lonetree

Washington D.C.

Fort Myers

Jacksonville

Miami

Orlando

Lawrenceville

Chicago

Maywood

Niles

Zion

Fort Wayne

Goshen

Indianapolis

Iowa City

Fairway

Baltimore

Bethesda

Boston

Ann Arbor

Detroit

Minneapolis

Rochester

Springfield

St Louis

Lincoln

Omaha

Las Vegas

Basking Ridge

Hackensack

Morristown

Albuquerque

Albany

Commack

New York

Rochester

Rockville Centre

The Bronx

Charlotte

Raleigh

Bismarck

Cincinnati

Columbus

Oklahoma City

Eugene

Hershey

Philadelphia

Charleston

Greenville

Chattanooga

Knoxville

Nashville

Austin

Dallas

Houston

San Antonio

Tyler

Salt Lake City

Fairfax

Richmond

Kennewick

Seattle

Vancouver

Yakima

Morgantown

Milwaukee

Kingswood

St Leonards

Westmead

South Brisbane

Bedford Park

Hobart

East Melbourne

Geelong

Heidelberg

Parkville

Perth

Antwerp

Bruges

Ghent

Salvador

Curitiba

Porto Alegre

Santo André

Rio de Janeiro

São Paulo

Edmonton

Vancouver

Winnipeg

Halifax

Toronto

Montreal

Saskatoon

Hradec Králové

Prague

Aalborg

Aarhus C

Copenhagen

Odense C

Roskilde

Argenteuil

La Tronche

Limoges

Paris

Lai Chi Kok

Hong Kong

Tuenmen

Budapest

Debrecen

Győr

Pécs

Szeged

Modena

Rome

Alessandria

Bologna

Cagliari

Cuneo

Genova

Milan

Napoli

Rionero in Volture

Rome

Rozzano

Torrette Di Ancona

Higashiku

Minamiku

Minamiku

Shōwamachi

Chikusa-ku

Suita

Aoba-ku

Chūōku

Isehara-shi

Kōtoku

Bergen

Oslo

Gdansk

Katowice

Krakow

L0dz

Olsztyn

Warsaw

Wroclaw

Ufa

Saint Petersburg

Kazan'

Moscow

Moskva

Saint Petersburg

Johannesburg

Pretoria

eManzimtoti

Bloemfontein

Cape Town

Goyang-si

Hwasun-gun

Seocho-gu

Busan

Daegu

Incheon

Jeonju

Seoul

Badalona

Barcelona

Marbella

Pamplona

Salamanca

Santiago de Compostela

Valencia

Changhua

Chiayi County 613

Tainan City

Taipei

Taoyuan

Ankara

Istanbul

Samsun

Truro

Aberdeen

Glasgow

Sutton

Cardiff

Birmingham

Canterbury

Exeter

Inverness

Leicester

Lincoln

Liverpool

London

Manchester

Norfolk

Northwood

Nottingham

Oxford

Romford

Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Takeda

INDUSTRY

NCT01712490 - A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter